Sherif el-Refai Understanding The Different Subsets Of Lung Cancer At Markey Cancer Center

Holding several advanced degrees in the area of pharmaceutical sciences, Sherif El-Refai devoted nearly 10 years of study to the eradication of cancer. In addition to serving in the University of Kanas College of Pharmacy Black Lab, where he conducted lung cancer research to assist in developing more efficient treatments, Sherif El-Refai serves the Markey Cancer Center in the position of oncology pharmacist.

In the study of lung cancer, several subsets of the disease exit. Researchers say that because of the existence of these multiple subsets, the approach of treating the disease should vary for each patient based on which subset their cancer falls into.

Cancer of the lung, like all cancers, results from an abnormality in the body’s basic unit of life, the cell. Normally, the body maintains a system of checks and balances on cell growth so that cells divide to produce new cells only when new cells are needed. Disruption of this system of checks and balances on cell growth results in an uncontrolled division and proliferation of cells that eventually forms a mass known as tumor.

Tumors can be benign or malignant; when we speak of “cancer,” we refer to those tumors that are malignant. Benign tumors usually can be removed and do not spread to other parts of the body. Malignant tumors, on the other hand, often grow aggressively locally where they start, but tumor cells also can enter into the bloodstream or lymphatic system and then spread to other sites in the body. This process of spread is termed metastasis; the areas of tumor growth at these distant sites are called metastases.

Since lung cancer tends to spread or metastasize very early after it forms, it is a very life-threatening cancer and one of the most difficult cancers to treat. While lung cancer can spread to any organ in the body, certain locations — particularly the adrenal glands, liver, brain, and bones — are the most common sites for lung cancer metastasis. By knowing the makeup of each subset and how they react to each type of therapy, the research will aid in improving patient outcomes.

Advertisements

Sherif El-Refai Is Adding significance In The Medical Department

Sherif El-Refai is an accomplished researcher and pharmacist who holds a PhD from the University of North Carolina at Chapel Hill and has even pursued his MBA from the University of Florida. When it comes to the level of proficiency in the field of pharmacy, Sherif El-Refai is committed to understanding all the aspects of the practice and has experience in developing and submitting business plans that incorporate pharmacy services into pre-existing medical departments. He holds certification in pharmacy-based immunization delivery; basic life support; and advanced cardiac life support, anticoagulation, hypertension and lipids, and diabetes.

As a pharmacist in Jersey City, Sherif El-Refai persued a particular interest in the treatment of cancer. A writer and presenter on the topic, Sherif El-Refai hoped to become a leading authority in chemotherapy and its use in complex cases. Further he broadened his experience that included pharmaceutical practice and research, while aiding significant discoveries in the field of pharmacogenomics.

As an active member of the American Pharmacists Association (APhA), Sherif El-Refai holds additional certifications in immunization, anticoagulation, and advanced cardiovascular life support (ACLS). At ACLS classroom program they instructed the students in recognising both respiratory and cardiac arrest, iin additon to symptomatic bradycardia and other peri-arrest conditions. They also addressed early management strategies for these medical emergencies, as well as as airways management, and relevant pharmacology.

Additionally, the course assisted healthcare providers with respect to instances of strokes or acute coronary syndromes. Focusing on the importance of cooperation in cardiovascular life support, the educational program also helped to present strategies for effective communication and leadership while working with a resuscitation team.

Sherif El-Refai : An Experienced Oncologist Pharmacist & Researcher on Lung Cancer

A longtime clinical researcher with a wealth of experience in pharmacogenomics & individualized therapy Sherif El-Refai established his career as an ambitious medical professional in New Jersey. Graduated from the Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill, he completed his clerkships on both coasts of the country by playing an active role in numerous outreach events.

Sherif El-Refai

Sherif El-Refai focused to serve the patient population of his local community while actively increasing his knowledge in the pharmaceutical industry. Since establishing his intrest in the medical field, Sherif El-Reafai has been passionate about all aspects of cancer treatment and hoped to become an expert in chemotherapy.

As an experienced pharmacist Sherif El-Refai futher pursued his PhD in pharmaceutical sciences at the University of Kentucky. Accomplished as an oncology pharmacist at the Markey Cancer Center, where he focused his research on lung cancer. In an order to make cancer treatment methods more successful he devoted his time and experience by donating to funds.

In his role role as an oncologist pharmacist Sherif El-Refai started researching on lung cancer, and even conducted Multidisciplinary Lung Cancer Program.The Lung Cancer Program also participated in clinical trials, which contributed to the discovery of new cancer treatments. In the terms to specialities at the Markey Caner Center he regularly treated patients with mesothelioma, bronchial carcinoid, esophageal cancer, and small- and non-small-cell lung cancer. With a team experts Sherif El-Refai utilized some of the latest advances in cancer treatment, from traditional radiation and chemotherapy regiments to the newest and most promising pharmaceuticals.

The Cancer Screening Program at the Markey Cancer Center

Markey Cancer Center pic
Markey Cancer Center
Image: ukhealthcare.uky.edu

Sherif El-Refai is a PhD student at the University of Kentucky where he studies pharmaceutical sciences with a focus on clinical and experimental therapeutics. An experienced clinical researcher, Sherif El-Refai currently serves as an oncology pharmacist at the University of Kentucky’s Markey Cancer Center.

The Markey Cancer Center is a healthcare and research institution that has been providing cancer treatment for more than two decades. The center, which is in Lexington, Kentucky, offers innovative technology and high-quality, individualized patient care provided by a team of leading cancer specialists. In addition, the center operates wellness programs such as the Cancer Screening Program.

The Cancer Screening Program operates in partnership with education programs, research groups, and healthcare providers to offer comprehensive cancer prevention and screening services. Screenings, which are free for individuals who meet eligibility requirements, are available for lung, ovarian, prostate, skin, breast, cervical, and colorectal cancers. In addition, the American Cancer Society collaborates with the Markey Cancer Center to provide recommendations related to screenings. For more information on the program, visit www.ukhealthcare.edu/markeypatients-families/cancer-screening/.

New Technology May Speed Cancer Research

Cancer Research pic
Cancer Research
Image: news.virginia.edu

In pursuit of a PhD in pharmaceutical sciences at the University of Kentucky College of Pharmacy, Sherif El-Refai also serves as an oncology pharmacist at the university’s Markey Cancer Center. As part of the Black Lab at the College of Pharmacy, Sherif El-Refai researches the ways in which gene expression affects patient responses to cancer treatments.

Under the leadership of researcher J. Julius Zhu, associate professor of pharmacology, a research team at the University of Virginia School of Medicine has created a new technique that lets scientists more quickly assess gene mutations and their effect. The technique uses lentivirus, a form of retrovirus similar to the human immunodeficiency virus (HIV), which replaces normal genes with mutated versions.

The technology allows scientists to assess the effect of each mutation on the body. It is more time and cost efficient than currently available methods of studying gene mutation, and thus will be more accessible to the typical research laboratory. With this new technology, research that would have once taken 10 years will take only three months.

Dr. Zhu has suggested that this advancement will allow physicians to develop better customized treatments. By identifying the type and nature of a gene mutation, physicians may be able to suggest interventions that are likely to generate the proper level of gene activity.

University of Kentucky Cancer Screening Helps Prevent Lung Cancer

Lung Cancer pic
Lung Cancer
Image: ukhealthcare.uky.edu

A pharmaceutical sciences PhD student at the University of Kentucky (UK), Sherif El-Refai is a translational researcher focused on immuno-oncology in lung cancer at the university’s Markey Cancer Center. To compliment his oncology pharmaceutical practice, Sherif El-Refai conducts research on lung cancer treatment, prevention, and diagnosis.

Lung cancer is the leading cause of cancer-related deaths in the United States. Every year, it kills more people than colorectal, prostate, and breast cancer combined. The best way to prevent lung cancer is to stop smoking. For those who smoke regularly, lung cancer screening is recommended to detect the cancer early and to reduce the risk of lung cancer death.

UK’s lung cancer screening program was designed for persons at risk of developing lung cancer. These include seniors older than 55, people who smoke or have recently quit smoking, and people who have been smoking a pack or more fa day or over 30 years. The screening uses a computed tomography scan to reveal suspicious cancerous spots in the lungs. Patients diagnosed with the cancer are referred to the university’s Markey Cancer Center, where a multidisciplinary team of medical care givers will commence treatment.

Research Indicates Histone Protein Inhibition as Cancer Treatment

Sherif El-Refai

Sherif El-Refai focuses his work on experimental and clinical interventions. Sherif El-Refai currently works within the University of Kentucky’s Black lab, where researchers use gene expression to develop targeted cancer treatments.

In March 2017, researchers at Rockefeller University announced the development of an intervention that may reduce tumor growth by regulating gene expression. The research centers on proteins known as histones, changes to which may activate or deactivate a gene. Reader proteins within the cell then bind to the altered histone and facilitate activity of the gene.

Cancer researchers have already identified a type of reader protein known as the BET protein, which can inhibit tumor growth. The new discovery from the research team at Rockefeller University involves a type of protein that has similar potential to the BET protein but that shares a particular feature known as a YEATS domain. Like the BET protein, a protein with the YEATS domain binds to histones affected by a chemical mark known as an acetyl group.

Although the relevance of this particular functionality is as yet unknown, researchers do know that proteins with the YEATS domain may fuse with the MLL protein in certain patients with leukemia. Researchers tested this function by deleting a YEATS domain protein known as ENL from leukemia cells in mice, who had a significantly improved prognosis following the transplant of ENL-depleted proteins.

Researchers are now working on developing combination therapies that combine YEATS domain blockage with existing drugs that work as bromodomain inhibitors. The hope is to further explore the potential of YEATS domain blockers not only in leukemia but also in cancers of other types.